On 20 July 2023, Sosei Group Corporation, which oversees GJE client and leading fully integrated biopharmaceutical company Heptares Therapeutics Limited, completed its acquisition of Idorsia’s pharmaceuticals business in Japan and APAC (ex-China).

A GJE team headed by Ian Jones, with associates Ash Earl and Charlie O’Neill, provided IP support in the acquisition of Idorsia by Sosei Group Corporation as part of the due diligence for Pivlaz® (clazosentan) and daridorexant – drugs used to treat cerebral vasospasm and insomnia respectively.

To see how GJE supports in-house IP teams, please click here or contact Ian, Ash or Charlie who would be delighted to hear from you.